Vivos Therapeutics Enters Agreement to Exercise 1,982,356 Warrants
Vivos Therapeutics has entered into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,982,356 shares originally issued in January 2023, November 2023, and February 20, 2024, at exercise prices ranging from $3.83 to $5.05 per share, at a reduced exercise price of $2.34 per share. The shares of common stock issuable upon exercise of the warrants are registered for resale pursuant to effective registration statement on Form S-3. The gross proceeds to the company from the exercise of the warrants are expected to be approximately $4.64 million, prior to deducting placement agent fees and offering expenses. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. As consideration for the exercise of such existing warrants for cash, the Company will issue in a private placement new unregistered warrants to purchase up to an aggregate of 3,964,712 shares of common stock at an exercise price of $2.09 per share, which warrants will be exercisable immediately upon issuance and, with respect to warrants to purchase up to 1,982,356 shares of common stock, will expire five years following the date of issuance, and with respect to warrants to purchase up to 1,982,356 shares of common stock, will expire twenty-four months following the date of issuance. The offering is expected to close on or about January 20, subject to satisfaction of customary closing conditions
